Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18807097 | METHODS OF MANUFACTURING DIMERIC ANTIBODIES | August 2024 | February 2025 | Allow | 6 | 1 | 0 | No | No |
| 18060135 | CD38 MODULATING ANTIBODY | November 2022 | January 2025 | Allow | 26 | 1 | 0 | No | No |
| 17933954 | HETERODIMERIC Fc FOR MAKING FUSION PROTEINS AND BISPECIFIC ANTIBODIES | September 2022 | May 2025 | Allow | 31 | 1 | 1 | Yes | No |
| 17698889 | CHIMERIC CELLS COMPRISING DENDRITIC CELLS AND ENDOTHELIAL CELLS RESEMBLING TUMOR ENDOTHELIUM | March 2022 | April 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17611054 | EPCAM BINDING PROTEINS AND METHODS OF USE | November 2021 | April 2025 | Allow | 42 | 0 | 0 | Yes | No |
| 17608738 | CLL-1 TARGETED IMMUNOTHERAPIES | November 2021 | May 2025 | Allow | 43 | 1 | 0 | No | No |
| 17507531 | ANTHRACYCLINE ANTIBODY-DRUG CONJUGATES AND USES THEREOF | October 2021 | May 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17604555 | ANTI-PD-1 ANTIBODIES AND USES THEREOF | October 2021 | May 2025 | Allow | 43 | 1 | 0 | No | No |
| 17603761 | ANTI AQP3 MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO EXTRACELLULAR DOMAIN OF AQUAPORIN 3 (AQP3) AND USE THEREOF | October 2021 | May 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17599377 | Engineered Variant Antibodies that Bind CD38 | September 2021 | June 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17441519 | GLYPICAN-3 (GPC-3) ANTIBODIES | September 2021 | April 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17310957 | ANTI-FXI/FXIA ANTIBODY AND USE THEREOF | September 2021 | December 2024 | Allow | 40 | 0 | 1 | Yes | No |
| 17403406 | ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF | August 2021 | March 2025 | Allow | 43 | 1 | 1 | No | No |
| 17399729 | Activatable Anti-CTLA-4 Antibodies and Uses Thereof | August 2021 | June 2025 | Allow | 46 | 1 | 1 | No | No |
| 17429672 | ANTI-MATRIX METALLOPROTEINASE 7 (MMP-7) INHIBITORY ANTIBODY AND USES THEREOF | August 2021 | February 2025 | Allow | 43 | 1 | 0 | Yes | No |
| 17331768 | Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains | May 2021 | March 2025 | Allow | 46 | 1 | 0 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner HECK, BRYAN WILLIAM works in Art Unit 1643 and has examined 15 patent applications in our dataset. With an allowance rate of 73.3%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 43 months.
Examiner HECK, BRYAN WILLIAM's allowance rate of 73.3% places them in the 29% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by HECK, BRYAN WILLIAM receive 0.80 office actions before reaching final disposition. This places the examiner in the 8% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by HECK, BRYAN WILLIAM is 43 months. This places the examiner in the 3% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +44.4% benefit to allowance rate for applications examined by HECK, BRYAN WILLIAM. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 97% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 100.0% of cases where such amendments are filed. This entry rate is in the 99% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 0% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.